MVA85A

MVA85A is a tuberculosis vaccine candidate that is currently under investigation. It is designed to be a booster to the BCG vaccine, the only currently available vaccine against tuberculosis. MVA85A is the first new tuberculosis vaccine candidate to reach Phase IIb clinical trials since the BCG vaccine was introduced in 1921.

History[edit | edit source]

MVA85A was developed by researchers at the University of Oxford. The vaccine candidate entered Phase IIb clinical trials in 2009, making it the first new tuberculosis vaccine candidate to reach this stage of development in nearly a century.

Design[edit | edit source]

MVA85A is designed to boost the immune response initiated by the BCG vaccine. It is a modified vaccinia virus that expresses the antigen 85A from Mycobacterium tuberculosis.

Clinical trials[edit | edit source]

In 2013, results from a Phase IIb clinical trial in South Africa were published. The trial involved nearly 3,000 infants who had previously been vaccinated with BCG. The results showed that MVA85A did not significantly boost the efficacy of the BCG vaccine.

Future development[edit | edit source]

Despite the disappointing results of the Phase IIb trial, research into MVA85A continues. Future trials may focus on different populations, such as adults or individuals with HIV.

See also[edit | edit source]

MVA85A Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.